Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214250 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
A Phase 1 study, sponsored by Parker Institute for Cancer Immunotherapy.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
NCT03214250 is a Phase 1 study that has completed, run by Parker Institute for Cancer Immunotherapy. The registered enrollment target is 129 participants.
The verdict
NCT03214250, a Phase 1 study, has completed, sponsored by Parker Institute for Cancer Immunotherapy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
Study Summary
The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
Interventions
- DRUG Nivolumab
- DRUG Nab-Paclitaxel
- DRUG Gemcitabine
- DRUG APX005M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2022-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03214250
The ClinicalTrials.gov registry entry for NCT03214250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Parker Institute for Cancer Immunotherapy, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03214250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03214250 about?
NCT03214250 is a clinical study titled "Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma". The main purposes of this study are to learn how effective the study drug combinations are in treating patients with metastatic pancreatic adenocarcinoma. The drug combinations are APX005M+Nivolumab+Gemcitabine+nab-Paclitaxel, or APX005M+Gemcitabine+nab-Paclitaxel.
What is the current status of trial NCT03214250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2017-07-21. Estimated completion is 2022-02-25.
What interventions are being tested in trial NCT03214250?
The interventions under investigation include: Nivolumab (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), APX005M (DRUG).
Who is sponsoring clinical trial NCT03214250?
This trial is sponsored by Parker Institute for Cancer Immunotherapy, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.